Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) have earned a consensus rating of “Buy” from the seventeen analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, eleven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $50.77.

A number of equities research analysts recently commented on the company. Cowen reaffirmed a “buy” rating and set a $66.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Monday, September 9th. Zacks Investment Research cut ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, September 11th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of ACADIA Pharmaceuticals in a research note on Tuesday, September 10th. BidaskClub cut ACADIA Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Leerink Swann raised ACADIA Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $21.00 to $50.00 in a research note on Friday, September 13th.

In other ACADIA Pharmaceuticals news, insider Eric Alejandro Miller sold 4,645 shares of the business’s stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $41.18, for a total value of $191,281.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael J. Yang sold 877 shares of the business’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $39.65, for a total value of $34,773.05. Following the completion of the transaction, the executive vice president now directly owns 2,500 shares of the company’s stock, valued at $99,125. The disclosure for this sale can be found here. Over the last three months, insiders sold 97,942 shares of company stock valued at $3,840,880. Insiders own 29.40% of the company’s stock.

A number of large investors have recently bought and sold shares of the business. Brinker Capital Inc. acquired a new position in ACADIA Pharmaceuticals in the third quarter valued at about $221,000. Whittier Trust Co. acquired a new position in ACADIA Pharmaceuticals in the third quarter valued at about $39,000. Coastal Investment Advisors Inc. acquired a new position in ACADIA Pharmaceuticals in the third quarter valued at about $36,000. Envestnet Asset Management Inc. acquired a new position in ACADIA Pharmaceuticals in the third quarter valued at about $383,000. Finally, Meeder Asset Management Inc. grew its stake in ACADIA Pharmaceuticals by 2,051.9% in the third quarter. Meeder Asset Management Inc. now owns 6,176 shares of the biopharmaceutical company’s stock valued at $221,000 after acquiring an additional 5,889 shares during the period. 94.88% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ ACAD traded up $3.27 during midday trading on Monday, hitting $43.22. The stock had a trading volume of 2,801,464 shares, compared to its average volume of 1,606,859. The company’s 50-day simple moving average is $37.36 and its 200 day simple moving average is $29.03. The firm has a market cap of $6.25 billion, a P/E ratio of -22.28 and a beta of 2.81. ACADIA Pharmaceuticals has a fifty-two week low of $14.01 and a fifty-two week high of $44.85. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.85 and a quick ratio of 6.79.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.46) by $0.08. ACADIA Pharmaceuticals had a negative return on equity of 70.97% and a negative net margin of 101.45%. The company had revenue of $83.21 million during the quarter, compared to analysts’ expectations of $72.50 million. During the same period last year, the firm earned ($0.51) EPS. The business’s revenue for the quarter was up 45.8% on a year-over-year basis. Equities analysts expect that ACADIA Pharmaceuticals will post -1.86 EPS for the current fiscal year.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Read More: What is Call Option Volume?

Analyst Recommendations for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.